Dendritic cells induce tolerance to pancreatic islets

树突状细胞诱导胰岛耐受

基本信息

  • 批准号:
    7300779
  • 负责人:
  • 金额:
    $ 33.83万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-07-01 至 2012-06-30
  • 项目状态:
    已结题

项目摘要

To silence autoimmune disease, we seek a means to expand in mice CD25+ CD4+ foxp3+ regulatory T cells (Treg) that are specific for disease producing autoantigens. We will pursue three themes that have begun through synergisms with Drs. Nussenzweig and Ravetch in this program: 1) The efficiency of antigen presentation in vivo can be greatly increased by targeted delivery of antigen within monoclonal antibodies to uptake receptors on dendritic cell (DCs). 2) A pivotal feature to the outcome of antigen presentation is the state of differentiation or maturation of the DC; this can be enhanced or blocked through selective ligation of activating and inhibitory FcyR respectively. 3) DCs are specialized antigen presenting cells for CD25+ foxp3+ Treg, being able to drive their expansion with maintenance of foxp3 expression and function (5) and to convert CD25- foxp3- T cells into CD25+ foxp3+ T reg (preliminary data). Therefore we will identify DC receptors, subsets and maturation states that are required to control the development and maintenance of antigen-specific T reg in the peripheral tissues of mice. Aim 1 will determine the DC requirements for the expansion of CD25+ CD4+ foxp3+ antigen-specific Treg in vivo, pursuing initial evidence that the 33D1 receptor on CDS- DCs is an effective pathway. Aim 2 will determine the DC requirements for the differentiation of CD25+ CD4+ foxp3+ antigen-specific Treg in vivo from CD25- CD4+ foxpS- progenitors, pursuing initial evidence that the DEC-205 receptor on CD8+ DCs is an effective pathway and that TGFp works in concert with antigen presenting DCs to generate typical antigen-specific foxp3+ T reg. Aim 3 will induce, expand and maintain antigen-specific Tregs from a naive polyclonal T cell repertoire, including capacity of DC-targeting antibodies to ligate activating and inhibitory Feyreceptors. By harnessing the biology of DCs in vivo, particularly by targeting antigens within monoclonal antibodies to uptake receptors expressed on DCs, and by controlling the state of differentiation or maturation of DCs, we will be able to define the priniciples for generating large numbers of disease specific regulatory T cells in intact mice. This should in turn translate into new targeted therapies and products required to control autoimmunity in patients in a much more disease specific manner than has previously been feasible.
为了抑制自身免疫性疾病,我们寻找了一种在小鼠体内扩增CD25+CD4+Foxp3+调节性T细胞的方法 (Treg)对产生自身抗原的疾病具有特异性。我们将继续探讨已经开始的三个主题 通过与Nussenzweig博士和Ravetch博士在这个项目中的协同作用:1)抗原的效率 通过靶向递送抗原单抗可大大提高体内的呈递能力 树突状细胞(DC)上的摄取受体。2)抗原呈递结果的一个关键特征是 DC分化或成熟的状态;这可以通过选择性地结扎DC来增强或阻止 分别激活和抑制FcyR。3)树突状细胞是CD25+的特异性抗原提呈细胞 Foxp3+Treg,能够通过维持Foxp3的表达和功能来驱动它们的扩张(5)和 将CD25-Foxp3-T细胞转化为CD25+Foxp3+T细胞(初步数据)。因此,我们将确定DC 控制细胞发育和维持所需的受体、亚群和成熟状态 小鼠外周组织中的抗原特异性T细胞。目标1将确定以下项目的DC要求 CD25+CD4+Foxp3+抗原特异性Treg在体内的扩增,寻求33D1的初步证据 CDS-DC上的受体是一条有效的途径。目标2将确定以下项目的DC要求 体内CD25+CD4+Foxp3+抗原特异性Treg与CD25-CD4+foxpS-祖细胞的分化 寻求CD8+DC表面DEC-205受体是有效途径的初步证据 与抗原提呈树突状细胞协同工作,产生典型的抗原特异性Foxp3+T受体。目标3将 从一个朴素的多克隆T细胞库中诱导、扩增和维持抗原特异性Tregs,包括 DC靶向抗体连接激活和抑制Fey受体的能力。通过利用 体内树突状细胞的生物学,特别是通过靶向摄取受体的单抗中的抗原 在DC上表达,通过控制DC的分化或成熟状态,我们将能够 确定在完整小鼠中产生大量疾病特异性调节性T细胞的原理。这 应该反过来转化为控制患者自身免疫所需的新的靶向治疗和产品 以一种比以前可行的更具疾病特异性的方式。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ralph Marvin Steinman其他文献

Ralph Marvin Steinman的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ralph Marvin Steinman', 18)}}的其他基金

DETECTION OF MHC CLASS II PEPTIDES
MHC II 类肽的检测
  • 批准号:
    8361586
  • 财政年份:
    2011
  • 资助金额:
    $ 33.83万
  • 项目类别:
DC-targeted DNA vaccines
DC 靶向 DNA 疫苗
  • 批准号:
    7774820
  • 财政年份:
    2009
  • 资助金额:
    $ 33.83万
  • 项目类别:
FACS
流式细胞仪
  • 批准号:
    7645166
  • 财政年份:
    2008
  • 资助金额:
    $ 33.83万
  • 项目类别:
Dendritic cells induce tolerance to pancreatic islets
树突状细胞诱导胰岛耐受
  • 批准号:
    7645165
  • 财政年份:
    2008
  • 资助金额:
    $ 33.83万
  • 项目类别:
FACS
流式细胞仪
  • 批准号:
    7300785
  • 财政年份:
    2007
  • 资助金额:
    $ 33.83万
  • 项目类别:
HUMAN LYMPHOCYTE ACTIVATION: ROLE OF DENDRITIC CELLS
人类淋巴细胞激活:树突状细胞的作用
  • 批准号:
    7206983
  • 财政年份:
    2005
  • 资助金额:
    $ 33.83万
  • 项目类别:
FACS calibur 4 color modular analytical flow cytometer
FACS calibur 4 色模块化分析流式细胞仪
  • 批准号:
    6577455
  • 财政年份:
    2003
  • 资助金额:
    $ 33.83万
  • 项目类别:
Dendritic Cells: Interfaces with Immunobiology/Medicine
树突状细胞:与免疫生物学/医学的接口
  • 批准号:
    6583501
  • 财政年份:
    2003
  • 资助金额:
    $ 33.83万
  • 项目类别:
CONFERENCE ON DENDRITIC CELLS
树突状细胞会议
  • 批准号:
    6287411
  • 财政年份:
    2001
  • 资助金额:
    $ 33.83万
  • 项目类别:
IMMUNITY TO MELANOMA VIA DENDRITIC CELLS
通过树突状细胞对黑色素瘤产生免疫力
  • 批准号:
    6191790
  • 财政年份:
    2000
  • 资助金额:
    $ 33.83万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 33.83万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 33.83万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 33.83万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 33.83万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 33.83万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 33.83万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 33.83万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 33.83万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 33.83万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 33.83万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了